Stockscreener 앱 받기
15.26
1.42%
-0.22
전일 마감가:
$15.48
열려 있는:
$15.39
하루 거래량:
170.17K
Relative Volume:
1.00
시가총액:
$485.04M
수익:
순이익/손실:
주가수익비율:
-
EPS:
-
순현금흐름:
1주 성능:
-9.60%
1개월 성능:
-31.17%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$14.77
$18.21
52주 변동 폭
$14.77
$27.99
BlossomHill Therapeutics, Inc. Common Stock Stock (BLSM) Company Profile
명칭
BlossomHill Therapeutics, Inc. Common Stock
전화
-
주소
-
Compare BLSM vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLSM
BlossomHill Therapeutics, Inc. Common Stock
|
15.26 | 485.04M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
239.46 | 95.60B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
798.85 | 82.25B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
852.08 | 53.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.16 | 42.33B | 5.76B | 514.49M | 1.10B | 4.4813 |
BlossomHill Therapeutics, Inc. Common Stock Stock (BLSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-01 | 개시 | Guggenheim | Buy |
| 2026-09-01 | 개시 | H.C. Wainwright | Buy |
| 2026-09-01 | 개시 | JP Morgan | Overweight |
BlossomHill Therapeutics, Inc. Common Stock 주식(BLSM)의 최신 뉴스
Latigo Biotherapeutics, Inc. Common Stock (LTGO) Earnings Reports & Dates - FXEmpire
Leerink Partners Boosts BlossomHill Therapeutics (NASDAQ:BLSM) Price Target to $40.00 - marketbeat.com
BlossomHill Therapeutics (NASDAQ:BLSM) Hits New 12-Month HighShould You Buy? - marketbeat.com
BlossomHill Therapeutics (NASDAQ:BLSM) Announces Earnings Results, Misses Estimates By $7.91 EPS - MarketBeat
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results - Stock Titan
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results - GlobeNewswire
BlossomHill Therapeutics (NASDAQ:BLSM) Stock Price Up 5.8%What's Next? - marketbeat.com
BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 12-Month HighWhat's Next? - marketbeat.com
BlossomHill stock surges on positive lung cancer trial data By Investing.com - Investing.com South Africa
An experimental lung cancer drug kept disease under control in 88% of 40 patients - Stock Titan
BlossomHill Therapeutics, Inc.'s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM) - marketbeat.com
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap UpHere's Why - marketbeat.com
BlossomHill Therapeutics (NASDAQ:BLSM) Stock Rating Upgraded by Guggenheim - marketbeat.com
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Given Average Rating of "Buy" by Brokerages - marketbeat.com
Patients whose lung cancer develops a specific resistance mutation after a targeted drug stops working have no approved pills aimed at it. BlossomHill Therapeutics plans to present updated trial data on Sept. 15. - Stock Titan
BlossomHill (NASDAQ: BLSM) insider buys at $16 and gets options - Stock Titan
OrbiMed adds BlossomHill Therapeutics (BLSM) IPO stake with insider buy - Stock Titan
BlossomHill Therapeutics Insider Bought Shares Worth $5,000,000, According to a Recent SEC Filing - Yahoo Finance
BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs - BioSpace
BlossomHill Therapeutics completes IPO and updates governance - TipRanks
BlossomHill Therapeutics shares fall in debut after IPO - Investing.com
BlossomHill Therapeutics Prices Upsized Nasdaq IPO - Yahoo Finance
Latham & Watkins Advises on BlossomHill Therapeutics’ Upsized US$150 Million IPO - Latham & Watkins LLP
BlossomHill Therapeutics Prices Upsized $150 Million Initial Public Offering | BLSM Stock News - Quiver Quantitative
BlossomHill Therapeutics, Inc.BLSMStock Price Today - Zacks Investment Research
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering - GlobeNewswire
BlossomHill Therapeutics (BLSM) director holds $13.59 option to 2036 - Stock Titan
BlossomHill Therapeutics prices $150M IPO at $16 per share - Investing.com
BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise - Seeking Alpha
BlossomHill Therapeutics files for Nasdaq IPO at up to $17 per share - Investing.com
BlossomHill Therapeutics files for Nasdaq IPO at up to $17 per share - Investing.com Nigeria
BlossomHill Therapeutics files for Nasdaq IPO under ticker BLSM - Investing.com
BlossomHill Therapeutics, Clinical-Stage Oncology Biotech, Files for Nasdaq Global Select Market IPO - TradingView
BlossomHill Therapeutics prices $150M IPO at $16 per share By Investing.com - Investing.com Nigeria
SGMT Stock Price and Chart — NASDAQ:SGMT - TradingView
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
Greenwave Technology Solutions, Inc. Common Stock (GWAV) Historical Quotes - nasdaq.com
PHAT Stock Price and Chart — NASDAQ:PHAT - TradingView
AQST Stock Price and Chart — NASDAQ:AQST - TradingView
ACRS Stock Price and Chart — NASDAQ:ACRS - TradingView
IRWD Stock Price and Chart — NASDAQ:IRWD - tradingview.com
BlossomHill Therapeutics, Inc. Common Stock (BLSM) 재무 분석
BlossomHill Therapeutics, Inc. Common Stock (BLSM)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
BlossomHill Therapeutics, Inc. Common Stock 주식 (BLSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Aug 10 '26 |
Buy |
16.00 |
625,000 |
10,000,000 |
2,714,279 |
| Schmid John P. | Director |
Aug 10 '26 |
Buy |
16.00 |
6,000 |
96,000 |
6,000 |
| Chen Bihua | Director |
Aug 10 '26 |
Buy |
16.00 |
312,500 |
5,000,000 |
3,614,034 |
| Keyes Jason A | Chief Financial Officer |
Aug 10 '26 |
Buy |
16.00 |
700 |
11,200 |
700 |
| Liptak Vincent Paul | General Counsel |
Aug 10 '26 |
Buy |
16.00 |
2,200 |
35,200 |
111,412 |
| Liptak Vincent Paul | General Counsel |
Aug 07 '26 |
Buy |
15.80 |
2,500 |
39,500 |
109,212 |
0.34%
자본화:
|
볼륨(24시간):